Combined, the increased activity of cathepsins B, L, S and K in the various types of cancer leads us to believe that the C3C assay would be a useful tool in assessing the cathepsin-mediated effects on the ECM turnover in cancer. The gene discussed is CTSS; the disease is cancer.